RC
SAGE

Roundview Capital’s Sage Therapeutics SAGE Stock Holding History

Roundview Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,260
Closed -$388K – 312
2023
Q2 		$388K Hold
8,260
– – 0.04% 256
2023
Q1 		$347K Hold
8,260
– – 0.04% 264
2022
Q4 		$315K Buy
+8,260
New +$315K 0.04% 253

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Roundview Capital's SAGE Position: Q3 2023 in Review

Roundview Capital sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 8,260 shares — an estimated $388K sold.

Roundview Capital first reported a position in SAGE in Q4 2022 and held it in 3 quarters. The position peaked at $388K in Q2 2023. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Roundview Capital reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Roundview Capital sold 8,260 Sage Therapeutics shares in Q3 2023, an estimated $388K.
  • Roundview Capital first reported a position in Sage Therapeutics in Q4 2022 and held it in 3 quarters.
  • Roundview Capital's Sage Therapeutics position peaked at $388K in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Roundview Capital's 13F filing for Q3 2023, filed 13 Nov 2023.